Main Conference Day 3Friday, 29 May 2026 - European Time GMT+1

Ficerafusp alfa, is a first-in-class EGFR-TGF-b bifunctional antibody. TGF-β signaling within the tumor microenvironment (TME) creates fibrotic, immunosuppressive barriers that impede tumor penetration of immune cells. Mechanistic insights from paired biopsies and preclinical studies reveal the importance of tumor targeted inhibition of TGF- b in breaking down barriers to tumor penetration. Ultimately, ficerafusp alfa’s tumor penetration has the potential to drive deep and durable responses that lead to long-term clinical benefits.

Stellabody® is a single point mutation in the CH3 region that facilitates “on-target assembly” of immune biologics that transforms killing or agonistic potency in multiple immune protein formats i.e. mAbs, bispecific antibodies, Fc-fusions and novel scaffolds. Stellabody biologics mediate greatly (10-100x) enhanced potency in head-to-head comparisons with the equivalent standard biologic including standard-of-care mAbs in oncology on primary patient-derived clinical samples and targets in infection and immunology.

Adeno-associated virus (AAV) gene therapies face challenges in tissue-specific delivery and safety. We have developed bispecific Altibody for precise AAV retargeting to muscle and CNS. This innovative "plug-and-play" approach enhances on-target transduction efficacy and safety in mice, marking a milestone in AAV retargeting strategies for gene therapy applications.